论文部分内容阅读
目的探讨肾透明细胞癌肺转移灶经分子靶向治疗后发生薄壁空洞改变的CT表现和临床意义。方法回顾性分析2例肾透明细胞癌经分子靶向药物Pazopanib治疗后肺转移灶出现薄壁空洞改变的相关病例临床及影像学资料。结果2例肾透明细胞癌原发灶切除术后,双肺多发实性转移灶,增强扫描多数病灶呈环形强化;经Pazopanib治疗3个月后大多数转移灶呈薄壁空洞样改变。病例1病情进展缓慢;病例2出现自发性气胸,2个月后死亡。结论分子靶向药物治疗促进了肾透明细胞癌肺转移灶坏死,有助于囊样薄壁空洞形成,但这种变化对预后的影响具有不确定性。
Objective To investigate the CT findings and clinical significance of the changes of parenchyma in lung metastases of clear cell carcinoma of the kidney after molecular targeted therapy. Methods The clinical and imaging data of 2 cases of clear cell carcinoma of the renal clear cell carcinoma treated with the molecular targeted drug Pazopanib were retrospectively analyzed. Results In 2 cases of primary clear cell carcinoma of renal cell carcinoma, multiple solid lesions in both lungs were observed, and most of the lesions showed ring-shaped enhancement. Most of the metastatic lesions showed thin-walled cavity-like changes after 3 months of treatment with Pazopanib. Case 1 The disease progressed slowly; case 2 spontaneous pneumothorax, died after 2 months. Conclusions Molecular targeted drug therapy can promote the necrosis of lung metastases of clear cell renal cell carcinoma and contribute to the formation of cyst-like thin-walled cavity. However, the influence of such changes on prognosis is uncertain.